Table 1.
Oral agents with counts and percents of patients out of the total sample (N=272) for each drug.
| CYTOTOXICS | |
| Temozolomide | 7 (2.6) |
| Tipiracil & Trifluridine | 1 (0.3) |
| Capecitabine | 92 (33.8) |
| KINASE INHIBITORS | |
| BRC-ABL Tyrosine Kinase Inhibitor | |
| Bosutinib | 1 (0.3) |
| Imatinib | 6 (1.8) |
| Dasatinib | 2 (0.7) |
| Nilotinib | 1 (0.3) |
| VEGF/VEGFR Inhibitor | |
| Axitinib | 3 (1.1) |
| Sorafenib | 11 (4.0) |
| Sunitinib | 8 (2.9) |
| Pazopanib | 22 (8.1) |
| Lenvatinib | 1 (0.3) |
| Regorafenib | 9 (3.3) |
| EGFR HER2/neu | |
| Erlotinib | 5 (1.8) |
| Afatinib | 1 (0.3) |
| Lapatinib | 1 (0.3) |
| ALK Inhibitor | |
| Crizotinib | 4 (1.5) |
| Ceritinib | 1 (0.3) |
| BRAF Inhibitor | |
| Dabrafenib | 7 (2.6) |
| Phospoinositide 3-Kinase Inhibitor | |
| Idelalisib | 1 (0.3) |
| Cyclin Dependent Kinase Inhibitor | |
| Palbociclib | 36 (13.2) |
| Bruton’s Tyrosine Kinase Inhibitor | |
| Ibrutinib | 7 (2.6) |
| SEX HORMONE INHIBITORS | |
| Enzalutamide | 18 (6.6) |
| Abiraterone acetate | 11 (4.0) |
| OTHER | |
| Immunomodulatory | |
| Lenalidomide | 10 (3.7) |
| Pomalidomide | 1 (0.3) |
| mTOR Inhibitors | |
| Everolimus | 11 (4.0) |
| Poly ADP Ribose Polymerase Inhibitor | |
| Olaparib | 1 (0.3) |